CSA-13 Against Psuedomonas Aeruginosa Biofilms

[enniob]

N8 Respiratory presented data at the NACFC demonstrating antimicrobial efficacy of CSA-13 against Psuedomonas aeruginosa (PA) biofilms. Specifically, a preclinical study was presented demonstrating its lead compound CSA-13's efficacy as an antimicrobial peptide mimic against Pseudomonas aeruginosa and the biofilms produced by its mucoid strain. You can read a recent post I made on Mucoid vs Non-mucoid Pseudomonas aeruginosa here. And you can read a post I made on the importance of targetting biofilms for treating CF lung infection here.

The study showed that the minimum inhibitory concentration (MIC) of CSA-13 (1.6-3.2 µg/ml) was unchanged in the presence of sputum from CF patients, while the MIC of tobramycin (the most common antibiotic for pulmonary P. aeruginosa infections) increased significantly (from 0.8 µg/ml to >64 mg/ml) in the presence of sputum from CF patients. CSA-13's MIC also remained unchanged whether tested in a tobramycin susceptible, or a tobramycin resistant strain (AGR 2).

"This is an encouraging study, as it demonstrates the ability of CSA-13 to remain effective even in the presence of sputum from a cystic fibrosis patient," said Paul B. Savage, MD, Department of Chemistry and Biochemistry, Brigham Young University. "Further, it confirms previous findings that the compound may continue to be effective even in antibiotic-resistant strains of P. aeruginosa. While antibiotic resistance continues to be a concern, we are seeing potential, at least in this context, to find solutions."

The study, which was presented as a poster at the North American Cystic Fibrosis Conference in Atlanta, GA, measured efficacy and the MIC of CSA-13 and tobramycin when combined with standard and tobramycin-resistant strains of P. aeruginosa. Sputum of cystic fibrosis patients was also added to each treatment to determine the impact of biofilm on each treatment.

"This preclinical study is promising on a number of fronts," said Dr. Michael Triplett, CEO of N8 Respiratory. "While it demonstrates the efficacy of our compound, CSA-13 in an extremely challenging more real-world like context, it also presents N8 with the opportunity to present real solutions to the medical community and CF patients."

PR source: http://t.co/2lg8vFDxaP

- Chris